FDA Warns of Increased Mortality Risk With Duvelisib Drug approved for adults with CLL/SLL Jul 01, 2022
Kidney Failure May Drive COVID Deaths in People With Sickle Cell Trait COVID-19 severity strongly linked with sickle cell anemia as well Jun 27, 2022
Brentuximab Vedotin Boosts Survival in Untreated Hodgkin Lymphoma ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment Jun 21, 2022
Studies Reinforce Prognostic Role for Circulating Tumor Cells in Myeloma At higher levels, different cutoffs show at least a doubling of PFS, OS hazard ratios Jun 13, 2022
FDA Panel Backs Gene Tx for Degenerative Brain Disorder in Kids Advisers unanimously recommend approval for pediatric ALD patients without HLA-matched donors Jun 10, 2022
Myeloma Trial Supports 'Personalized Approach' to Upfront Transplant DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored Jun 06, 2022
Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphoma Significantly more responses, CRs with zanubrutinib-obinutuzumab versus anti-CD20 drug alone Jun 05, 2022
Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin Lymphoma Combo regimen offers "a new standard for front-line therapy," researcher says Jun 04, 2022
Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma Patients BTK inhibitor plus chemoimmunotherapy increased progression-free survival by over 2 years Jun 03, 2022
FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
Unprecedented PFS Improvement in Relapsed Multiple Myeloma Three-year median with addition of isatuximab to proteasome inhibitor backbone May 26, 2022
Elotuzumab Combination Disappoints in Newly Diagnosed Myeloma Study failed to replicate positive results seen in relapsed/refractory setting May 11, 2022
Corticosteroids Linked to Pain Events in Patients With Sickle Cell Disease Hospitalization risk for vaso-occlusive episodes four times higher after exposure May 02, 2022
Promising Data for Allo-Transplant After CAR T-Cell Failure in LBCL Durable responses with no unexpected or prolonged safety issues Apr 27, 2022
Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS 1-year relapse-free survival rate of 60% with maintenance therapy after transplant Apr 25, 2022
BTK Inhibitor Shows Potential in Immune Thrombocytopenia Across doses, 40% of heavily pretreated patients responded to oral rilzabrutinib Apr 13, 2022
Bispecific Antibody-NK Cell Complex Impresses in Early Hodgkin/NHL Trial Objective responses in 89% of patients with no CRS, neurotoxicity, or graft-versus-host disease Apr 11, 2022
9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancer Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
Cancer May Heighten Odds of Guillain-Barre Syndrome Link strongest with hematologic malignancies as well as prostate, breast, and respiratory cancers Mar 03, 2022
Dear Blood Donors, You've Given Me the Gift of Life I offer my gratitude through acceptance, acknowledgement, and reflection Feb 06, 2022
FDA Concerned About Safety of Lymphoma Drug Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
Finally, a 'New Standard' for Severe Aplastic Anemia After 3 decades of failures, RACE trial shows superiority of new first-line regimen Jan 05, 2022
Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survival Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022
Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
Gene Therapy Resolves Severe Pain Events in Sickle Cell Disease LentiGlobin also normalized hemoglobin and reduced hemolysis markers Dec 15, 2021
Can Dasatinib Dose Be Halved in Low-Risk CML? Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
R-CHOP Toppled in First-Line DLBCL Trial Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
Ξ²-Thalassemia Patients Go Transfusion-Free With Gene Therapy Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
R2 Maintenance for Elderly MCL Patients Worth the Risk? Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-T Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma Patients Overall response rate of 96% with ibrutinib-rituximab, but cardiotoxicity a possible issue Nov 29, 2021
Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
Pegylated Interferon Wins FDA Approval for Polycythemia Vera Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
